Alzheimer'
Conditions
Interventions
Patients who titrated at 1-week intervals
Patients who titrated at 2-week intervals
Patients who titrated at 4-week intervals
Sponsors
Graduate School of Medicine, Osaka City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients by whom the concent in the document was got. 2)Patients who are 50 to 85 years old at the assesment of baseline 3)male or female without the possibility of pregnancy 4)Patients diagnosed as dementia of the Alzheimers type by the Diagnostic and Statistical Manual of Mental Disorders 4th edition criteria 5)Patients who diagnosed as probable AD according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimers Disease and Related Disorders Association criteria 6)MMSE at baseline of patients are 23 points or less and 10 or more points 7)Patients who were able to do normally reading, writing or spearking till before the onset of dementia 8)Patients who were cooperative and able to undergo medical tests and observation by oneself or with assisit of caregiver 9)Patients who have a caregiver throughout the study. The caregiver was required to be the primary caregiver and to be willing to accept responsibility for supervising the treatment, assessing the condition of the patient throughout the study and for providing input to efficacy assessments according to protocol requirements.
Exclusion criteria
Exclusion criteria: 1)patents who have the problem of urination 2)patients who have the skin disease 3)patients who have sight and hearing handicaps and an advanced speech impediment 4)patient whom the principal investigator or subinvestigator judged to be unsuitable as an object of this research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The evaluation of the safety, tolerability and adverse event(frequency of nausea and vomit, change of dietary intake) of rivastigmine patch in patients who titrated at short interval to the maintenace dose | — |
Secondary
| Measure | Time frame |
|---|---|
| ADAS-J cog MMSE Medication compliance Change of caregiver burden | — |
Countries
Japan
Contacts
Public ContactHiroyuki Shimada
Graduate School of Medicine, Osaka City University Geriatrics and Neurology
Outcome results
None listed